Cancer organoids: A platform in basic and translational research

Xin Ma; Qin Wang; Guozheng Li; Hui Li; Shouping Xu; Da Pang

doi:10.1016/j.gendis.2023.02.052

您当前的位置：

首页 >

文章列表页 >

Cancer organoids: A platform in basic and translational research

Review article | 更新时间：2024-02-04

- Cancer organoids: A platform in basic and translational research
- Genes & Diseases Vol. 11, Issue 2, (2024)
- 作者机构：
  
  1. Department of Pharmacology (The State-Province Key Laboratories of Biomedicine-Pharmaceutics of China), College of Pharmacy of Harbin Medical University,Heilongjiang,Harbin,China,150086
  2. Department of Breast Surgery, Harbin Medical University Cancer Hospital,Heilongjiang,Harbin,China,150081
  3. Heilongjiang Academy of Medical Sciences,Heilongjiang,Harbin,China,150086
  4. Sino-Russian Medical Research Center, Harbin Medical University Cancer Hospital,Heilongjiang,Harbin,China,150081
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2023.02.052
  CLC：
- Published：2024，
  
  Published Online：1 March 2024，
扫描看全文
Xin Ma, Qin Wang, Guozheng Li, et al. Cancer organoids: A platform in basic and translational research. [J]. Genes & Diseases 11(2).(2024)
DOI：

Xin Ma, Qin Wang, Guozheng Li, et al. Cancer organoids: A platform in basic and translational research. [J]. Genes & Diseases 11(2).(2024) DOI： 10.1016/j.gendis.2023.02.052.

摘要

Abstract

n accumulation of previous work has established organoids as good preclinical models of human tumors

facilitating translation from basic research to clinical practice. They are changing the paradigm of preclinical cancer research because they can recapitulate the heterogeneity and pathophysiology of human cancers and more closely approximate the complex tissue environment and structure found in clinical tumors than

in vitro

cell lines and animal models. However

the potential applications of cancer organoids remain to be comprehensively summarized. In the review

we firstly describe what is currently known about cancer organoid culture and then discuss in depth the basic mechanisms

including tumorigenesis and tumor metastasis

and describe recent advances in patient-derived tumor organoids (PDOs) for drug screening and immunological studies. Finally

the present challenges faced by organoid technology in clinical practice and its prospects are discussed. This review highlights that organoids may offer a novel therapeutic strategy for cancer research.

关键词

Keywords

Drug assaysImmunotherapyMechanism researchOrganoidsPrecision medicine

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy

The link between intracellular calcium signaling and exosomal PD-L1 in cancer progression and immunotherapy

Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy

Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics

Related Author

Pengcheng Zhao

Longyan Xie

Lei Yu

Ping Wang

Md Rakibul Alam

Md Mizanur Rahman

Zhiguo Li

Sunny Kumar

Related Institution

Tongji University Cancer Center, Shanghai Tenth People's Hospital, School of Medicine, Tongji University

School of Life Sciences and Medicine, Shandong University of Technology

Department of Medicine (Nephrology), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta T6E2H7

Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky

Department of Economics, Bethune College, University of Calcutta, Kolkata

⁰